French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday that the European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes in adults and children eight years and older with stage 2 T1D.
This approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use and is based on the TN-10 phase 2 study, which showed a median two-year delay in progression to stage 3 compared with placebo.
In the study, 57% of patients receiving Teizeild remained in stage 2 T1D versus 28% in the placebo group. The safety profile was consistent with prior trials, with the most common adverse events being transient lymphopenia in 75% of participants and rash in 36%.
Teizeild (known as Tzield outside the EU) is also approved in the US, UK, China, Canada, Israel, Saudi Arabia, UAE, and Kuwait. It represents the first disease-modifying therapy for T1D in the European Union.
Sanofi said that it has opted not to pursue a second application for Teizeild in recently diagnosed stage 3 T1D at this time. Other regulatory reviews are ongoing.
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
GlycoNex submits marketing authorisation application for denosumab biosimilar to Japanese regulator
Akeso publishes ivonescimab Phase II study results in Nature Medicine
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
Minghui Pharmaceutical licenses IGF-1R antibody to ASKA Pharmaceutical in Japan